That is my point, the science is spectacular and should be very valuable. The fact that it is not is what has me worried. I do not know what i would do but I am not the CEO. There are OTC stocks that make their way to $5+ and uplist, so blaming the OTC can’t be it. There are companies that get partnership deals when in phase 2, so the status of pro140 in development is very much not the problem. The market size, the expanding indications, all of it points to a company that should be gaining value at a dramatic clip, but it is not. If these reasons are not enough to question mgmt then I don’t know what is. I sincerely hope everything plays out in a very positive way, not just for investors but for thousands of very sick people. I can safely say I have been invested in CYDY longer than anyone and likely own more shares than most, my belief in a bright future is as solid as anyone’s but when there is something not right I question it. We have not gotten a reason for the value of this company not matching anywhere close to what it should be. I doubt there is any bad reason fo the annual mtg date change, we are all looking at this too close and it is likely just as schedule thing or something taking a little longer in the Pestell deal.